Mainz Biomed Presents New Study Data For ColoFuture And EAArly DETECT Study Performance With Sensitivity For CRC Of 92% And 82% For Advanced Adenomas, Including 95.8% Detection Of High-Grade Dysplasia
Mainz Biomed Presents New Study Data For ColoFuture And EAArly DETECT Study Performance With Sensitivity For CRC Of 92% And 82% For Advanced Adenomas, Including 95.8% Detection Of High-Grade Dysplasia
New study data confirmed previous ColoFuture and eAArly DETECT study performance with sensitivity for CRC of 92% and 82% for advanced adenomas, including 95.8% detection of high-grade dysplasia
新的研究數據證實了先前 ColoFuture 和 eAArly DETECT 研究在 CRC 靈敏度方面的表現爲 92％ 和晚期腺瘤爲 82％，包括高級別非典型增生的檢測率爲 95.8％。
Results from pooled study represents the third consecutive confirmation of the consistently good performance of Mainz Biomed's mRNA biomarkers to detect CRC and precancerous lesions
彙總研究結果代表了邁因茨生物醫學的 mRNA 生物標誌物連續第三次證實用於檢測 CRC 和癌前病變的表現一直非常出色。
BERKELEY, Calif. and MAINZ, Germany, June 03, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ), a molecular genetics diagnostic company specializing in the early detection of cancer, presented pivotal data from its largest cohort to date during a poster presentation at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting in Chicago, Illinois, and online. This data combines results from the ColoFuture and eAArly DETECT studies including additional patients collected since the first reported study results, demonstrating the significance of its innovative screening approach.
2024年6月3日，加州伯克利和德國邁因茨，分子遺傳學診斷公司Mainz Biomed N.V。（納斯達克股票代碼MYNZ），在美國臨床腫瘤學會（ASCO）2024年年會上和線上展示了迄今爲止其最大Cohort的關鍵數據。其中包括ColoFuture和eAArly DETECT研究結果，以及自首次報告研究結果以來收集的更多病人，展示了其創新篩查方法的重要性。
譯文內容由第三人軟體翻譯。